SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)
This is a single-arm, sequential study assessing the efficacy and safety of SMET12 and Toripalimab combined chemotherapy in patients with EGFR positive advanced non-small cell lung cancer (NSCLC) : first-line treatment or failed from first-line immune checkpoint inhibitor treatment.The primary objective is to evaluate the anti-tumor activity and safety of SMET12 and Toripalimab combined chemotherapy in patients with EGFR positive advanced NSCLC.
EGFR Positive Non-small Cell Lung Cancer
DRUG: SMET12|DRUG: SMET12|DRUG: SMET12
incidence of adverse events, Adverse events incidence refers to the frequency of adverse events, 1 year|rate of adverse events, All adverse events will also be rated based on the NCI CTCAE version 5.0., 1 year|Laboratory aberrations, Laboratory outliers refer to measurement results that significantly deviate from the normal reference range in laboratory testing., 1 year
disease control rate, Disease control rate: DCR, 1 year|Progression-free survival, Progression-free survival (PFS) as assessed by the investigators according to RECIST 1.1 criteria, 1 year|DOR（ Duration of Response）, Duration of response (DoR) is defined as the time from first confirmed response (complete response or partial response) to the date of the initial objectively documented tumor progression as determined per investigator assessment using RECIST 1.1 criteria or death due to any cause, whichever occurs first., 1 year
This is a single-arm, sequential study assessing the efficacy and safety of SMET12 and Toripalimab combined chemotherapy in patients with EGFR positive advanced non-small cell lung cancer (NSCLC) : first-line treatment or failed from first-line immune checkpoint inhibitor treatment.The primary objective is to evaluate the anti-tumor activity and safety of SMET12 and Toripalimab combined chemotherapy in patients with EGFR positive advanced NSCLC.